Compare FORTY & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORTY | SRPT |
|---|---|---|
| Founded | 1985 | 1980 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1998 | 2000 |
| Metric | FORTY | SRPT |
|---|---|---|
| Price | $125.72 | $23.21 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 29 |
| Target Price | N/A | ★ $25.85 |
| AVG Volume (30 Days) | 412.0 | ★ 2.8M |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.99 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.65 | ★ $7.13 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $102.01 | $14.68 |
| 52 Week High | $190.56 | $25.32 |
| Indicator | FORTY | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 64.64 | 74.39 |
| Support Level | $103.12 | $15.40 |
| Resistance Level | $134.92 | $23.71 |
| Average True Range (ATR) | 0.45 | 1.30 |
| MACD | 2.53 | 0.42 |
| Stochastic Oscillator | 100.00 | 99.83 |
Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.